RoActemra - direct healthcare professional communication (DHPC)

tocilizumab

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Direct healthcare professional communication (DHPC): RoActemra (tocilizumab) - Temporary Supply Shortage for 162 mg solution for subcutaneous injection (pre-filled syringe and pre-filled pen) and RoActemra 20mg/mL concentrate for solution for infusion(IV)

Dissemination date: 03/09/2021

Key facts

• Medicine name:
  RoActemra
• Active substance:
  tocilizumab
• Therapeutic area (MeSH):
  • Arthritis, Rheumatoid
  • Arthritis, Juvenile Rheumatoid
  • Cytokine Release Syndrome
• DHPC type:
  Medicine shortage
• Human ATC codes:
  L04AC07
• Dissemination date:
  03/09/2020